Report: Vertex's Incivek was fastest drug launch ever; Gilead's sofosbuvir excels in study;

@FierceBiotech: Popular yesterday: Feds launch probe of AstraZeneca's controversial late-stage Brilinta study. Article | Follow @FierceBiotech

@JohnCFierce: NovaQuest lands $459M fund for goal-line dealmaking--That's $1.2B for today. More | Follow @JohnCFierce

@DamianFierce: GlobeImmune pulls plug on $75M IPO despite still-bubbling market. Article | Follow @DamianFierce

@EmilyMFierce: Scripps Research scientists reach major milestone w/ HIV research, paving wave for new vaccine efforts. FierceBiotech Research story | Follow @EmilyMFierce

> Gilead Sciences' ($GILD) sofosbuvir has shown promise for hepatitis C patients with transplanted livers, providing benefits for many with no other treatment options. More

> Vertex's ($VRTX) hepatitis C treatment Incivek has unseated Pfizer's ($PFE) arthritis therapy Celebrex with the fastest drug launch ever, according to EvaluatePharma. Story

> Quintiles ($Q), the world's largest CRO, is counting on an increase in industry-wide R&D to boost its profits this year. News

> Sequenom's ($SQNM) shares dropped more than 22% after a federal judge invalidated patents tied to its prenatal diagnostic test. Story

Medical Device News

@FierceMedDev: Sequenom vows to appeal court decision invalidating prenatal test patent. More | Follow @FierceMedDev

@MarkHFierce: PerkinElmer said the government shutdown could, in part, affect revenue projections for the year. ICYMI yesterday | Follow @MarkHFierce

@MichaelGFierce:  | Follow @MichaelGFierce

> Boston Scientific closes $275M deal for Bard's electrophysiology arm. Story

> Gore begins long trek to pay back Bard in vascular graft patent ruling. Item

> Smith & Nephew reports improved Q3 and names new chairman. Article

Pharma News

@FiercePharma: Thursday's top story: Novo Nordisk recruiting 400 U.S. sales reps as growth decelerates. Article | Follow @FiercePharma

@EricPFierce: FDA has new plan to arrest drug shortages. Its ultimate solution is for drugmakers to improve quality. Story | Follow @EricPFierce

@CarlyHFierce: Once again, Bayer's new drugs power pharma sales upward. ICYMI yesterday | Follow @CarlyHFierce

> Mylan looks to 2014 for big growth. Report

> Teva says it may have violated bribery laws around the world. More

> Vertex's Incivek unseats Celebrex as fastest drug launch ever. Story

Suggested Articles

It’s been a good year for Intellia: One of its founders, Jennifer Doudna, Ph.D., nabbed the Nobel Prize in Chemistry for her CRISPR research.

After stints at Eli Lilly, Boehringer Ingelheim and Bristol Myers Squibb, Sid Kerkar, M.D., is hopping over to a small biotech.

Two long noncoding RNAs called TROLL-2 and TROLL-3 influence protein signaling to drive the progression of breast cancer, a new study revealed.